PI3K Inhibition Enhances Doxorubicin-Induced Apoptosis in Sarcoma Cells

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Marklein, Diana ^a   Graab, Ulrike ^b   Naumann, Ivonne ^b   Yan, Tiandong ^c   Ridzewski, Rosalie ^a   Nitzki, Frauke ^a   Rosenberger, Albert ^a   Dittmann, Kai ^a   Wienands, Jürgen ^a   Wojnowski, Leszek ^c   Fulda, Simone ^b   Hahn, Heidi ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; AZACITIDINE; BORTEZOMIB; CASPASE 3; DOXORUBICIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PIOGLITAZONE; PROTEIN BAX; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRION; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; SARCOMA; SARCOMA CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CYTOCHROMES C; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; FURANS; GENE EXPRESSION; HUMANS; INDAZOLES; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIDINES; PYRIMIDINES; SARCOMA; SULFONAMIDES; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84871815731     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052898     Document Type: Article

References (51)

1. Blay JY, (2011) Updating progress in sarcoma therapy with mTOR inhibitors. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 22: 280-7.
2. Gatta G, Capocaccia R, De Angelis R, Stiller C, Coebergh JW, (2003) Cancer survival in European adolescents and young adults. Eur J Cancer 39: 2600-10.
3. Stiller CA, Parkin DM, (1994) International variations in the incidence of childhood soft-tissue sarcomas. Paediatric and perinatal epidemiology 8: 107-19.
4. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, et al. (2001) Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19: 1238-47.
5. Gortzak E, Azzarelli A, Buesa J, Bramwell VH, van Coevorden F, et al. (2001) A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 37: 1096-103.
6. Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F, Beretta G, (1970) Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 30: 2572-82.
7. O'Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, et al. (1973) Phase II evaluation of adriamycin in human neoplasia. Cancer 32: 1-8.
8. Tan C, Etcubanas E, Wollner N, Rosen G, Gilladoga A, et al. (1973) Adriamycin-an antitumor antibiotic in the treatment of neoplastic diseases. Cancer 32: 9-17.
9. Bergeron C, Thiesse P, Rey A, Orbach D, Boutard P, et al. (2008) Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease. Eur J Cancer 44: 427-31.
10. Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, et al. (1988) The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 61: 209-20.
11. Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, et al. (1993) The Intergroup Rhabdomyosarcoma Study-II. Cancer 71: 1904-22.
12. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, et al. (1995) The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13: 610-30.
13. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE, (1998) Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 27: 53-68.
14. Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE, (2005) Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs 7: 187-202.
15. Takahashi-Hyodo SA, Sakamoto-Hojo ET, Takahashi CS, (1999) Interaction effects of 5-azacytidine with topoisomerase II inhibitors on CHO cells, as detected by cytogenetic analysis. Mutation research 431: 13-23.
16. Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, et al. (2007) Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. Journal of neuro-oncology 85: 159-70.
17. Kanbe E, Abe A, Towatari M, Kawabe T, Saito H, et al. (2003) DR1-like element in human topoisomerase IIalpha gene involved in enhancement of etoposide-induced apoptosis by PPARgamma ligand. Experimental hematology 31: 300-8.
18. Congdon LM, Pourpak A, Escalante AM, Dorr RT, Landowski TH, (2008) Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). Biochem Pharmacol 75: 883-90.
19. Xu J, Zhou JY, Tainsky MA, Wu GS, (2007) Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2′-deoxycytidine sensitizes human breast cancer cells to adriamycin. Cancer Res 67: 1203-11.
20. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, et al. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-6.
21. Biehn SE, Moore DT, Voorhees PM, Garcia RA, Lehman MJ, et al. (2007) Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Annals of hematology 86: 211-6.
22. Crose LE, Linardic CM, (2011) Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma. Sarcoma 2011: 756982.
23. Wan X, Helman LJ, (2007) The biology behind mTOR inhibition in sarcoma. Oncologist 12: 1007-18.
24. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, et al. (2008) Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 68: 6271-80.
25. Bender A, Opel D, Naumann I, Kappler R, Friedman L, et al. (2011) PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene 30: 494-503.
26. Raynaud FI, Eccles SA, Patel S, Alix S, Box G, et al. (2009) Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 8: 1725-38.
27. Goodrich LV, Milenkovic L, Higgins KM, Scott MP, (1997) Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 277: 1109-13.
28. Hacker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, et al. (2009) Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 28: 3097-110.
29. Mohr A, Zwacka RM, Debatin KM, Stahnke K, (2004) A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c release. Cell Death Differ 11: 1153-4.
30. Stahnke K, Mohr A, Liu J, Meyer LH, Karawajew L, et al. (2004) Identification of deficient mitochondrial signaling in apoptosis resistant leukemia cells by flow cytometric analysis of intracellular cytochrome c, caspase-3 and apoptosis. Apoptosis 9: 457-65.
31. Fan L, Pepicelli CV, Dibble CC, Catbagan W, Zarycki JL, et al. (2004) Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 145: 3961-70.
32. Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, et al. (2002) Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res 62: 2034-42.
33. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE, (1983) Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res 43: 3417-21.
34. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B, (2000) Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 275: 33585-92.
35. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, et al. (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-30.
36. Liu F, Liu S, He S, Xie Z, Zu X, et al. (2010) Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells. Oncol Rep 23: 1469-75.
37. Han Z, Hong L, Han Y, Wu K, Han S, et al. (2007) Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res 26: 261-8.
38. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, et al. (2007) Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21: 427-38.
39. Lee JT Jr, Steelman LS, McCubrey JA, (2004) Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 64: 8397-404.
40. Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, et al. (1998) Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci U S A 95: 14681-6.
41. Murphy KM, Streips UN, Lock RB, (2000) Bcl-2 inhibits a Fas-induced conformational change in the Bax N terminus and Bax mitochondrial translocation. J Biol Chem 275: 17225-8.
42. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-8.
43. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ, (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-40.
44. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, et al. (2008) The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. Journal of medicinal chemistry 51: 5522-32.
45. Cortes F, Pastor N, (2003) Induction of endoreduplication by topoisomerase II catalytic inhibitors. Mutagenesis 18: 105-12.
46. Rabbani A, Finn RM, Ausio J, (2005) The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioessays 27: 50-6.
47. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
48. Beck WT, Morgan SE, Mo YY, Bhat UG, (1999) Tumor cell resistance to DNA topoisomerase II inhibitors: new developments. Drug Resist Updat 2: 382-9.
49. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, et al. (2005) Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 65: 9226-35.
50. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, et al. (2008) Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111: 379-82.
51. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, et al. (2010) NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16: 530-40.